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ABSTRACT  
Although the spliceogenic nature of the BRCA2 c.68-7T>A variant has been demonstrated, its 
association with cancer risk remains controversial. In this study, we accurately quantified by 
real-time PCR and digital PCR the BRCA2 isoforms retaining or missing exon 3. In addition, 
the combined odds ratio for causality of the variant was estimated using genetic and clinical 
data, and its associated cancer risk was estimated by case-control analysis in 83,636 
individuals. Co-occurrence in trans with pathogenic BRCA2 variants was assessed in 5,382 
families. Exon 3 exclusion rate was 4.5-fold higher in variant carriers (13%) than controls 
(3%), indicating an exclusion rate for the c.68-7T>A allele of approximately 20%. The 
posterior probability of pathogenicity was 7.44 x 10
-115
. There was neither evidence for 
increased risk of breast cancer (OR 1.03; 95% CI 0.86-1.24), nor for a deleterious effect of 
the variant when co-occurring with pathogenic variants. Our data provide for the first time 
robust evidence of the non-pathogenicity of the BRCA2 c.68-7T>A. Genetic and quantitative 
transcript analyses together inform the threshold for the ratio between functional and altered 
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BRCA2 isoforms compatible with normal cell function. These findings might be exploited to 
assess the relevance for cancer risk of other BRCA2 spliceogenic variants. 
KEYWORDS: 
BRCA2, spliceogenic variants, multifactorial likelihood analysis, quantitative real-time PCR, 
digital PCR 
INTRODUCTION 
BRCA1 (MIM# 113705) and BRCA2 (MIM# 600185) are tumor suppressor genes and their 
inactivation promotes cancer development. Carriers of germline pathogenic variants in these 
genes are at high risk of developing breast and ovarian cancers, and BRCA1/2 gene testing 
has become a widely used procedure in the clinical management of families suspected of 
hereditary susceptibility to these malignancies. The individuals within these families, 
identified as at-risk based on their genetic profile, may benefit from risk-reduction options. 
However, the usefulness of genetic testing relies on the ability to ascertain the pathogenic 
nature of the identified genetic variants, which is not necessarily straightforward for small in-
frame deletions and insertions, variants in regulatory sequences, missense, synonymous and 
intronic changes, and variants introducing premature protein truncating codons at the 3 end 
of the coding sequence.  
The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) 
has developed and documented criteria aimed at determining the clinical significance of 
sequence variants in BRCA genes (http://www.enigmaconsortium.org). The classification, 
based on a 5-class system (Plon et al., 2008), is intended to differentiate high risk variants 
(risk equivalent to that of protein-truncating pathogenic variants), including pathogenic and 
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likely pathogenic variants (class 5 and 4, respectively), from variants with low or no risk, 
including not pathogenic and likely not pathogenic variants (class 1 and 2, respectively). 
Variants for which clinical significance is unclear are placed in class 3 and are referred to as 
variants of uncertain significance (VUSs). 
One controversial variant in BRCA2 is c.68-7T>A, which lies upstream of the acceptor splice 
site of exon 3. This variant (rs81002830) has been reported in several populations worldwide 
with an allelic frequency ranging from 0.02% in East Asians to 0.5% in non-Finnish 
Europeans (Lek et al., 2016). Several authors have reported c.68-7T>A being spliceogenic, 
i.e. able to alter normal pre-mRNA splicing. In particular, using semi-quantitative 
approaches, it has been documented that the variant leads to an increase of the naturally-
occurring transcripts lacking exon 3 (∆3) (Houdayer et al., 2012; Jarhelle et al., 2016; Sanz et 
al., 2010; Thery et al., 2011; Vreeswijk et al., 2009). A competitive quantitative PCR analysis 
estimated that the proportion of the ∆3 transcript compared to full-length was approximately 
25% in variant samples versus 4% in normal samples (Muller et al., 2011). More recently, 
segregation analyses in two families indicated that the variant did not segregate in the 
affected branches (Santos et al., 2014). Although a few of the above studies tentatively 
classified the variant as benign or likely benign, they do not provide robust genetic evidence 
to justify this conclusion. Conversely, a recent paper asserted that the variant was associated 
with breast cancer, based on a relatively limited case-control association study in the 
Norwegian population (Møller and Hovig, 2017). 
As a consequence, to date the classification of c.68-7T>A reported in databases aggregating 
information on genomic variations has remained inconclusive. In particular, ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/, last updated: Feb 1, 2018) reports conflicting 
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interpretations classifying the variant as benign (seven entries), likely benign (nine entries) 
and of uncertain significance (four entries). Moreover, the BIC (Breast Cancer Information 
Core, http://research.nhgri.nih.gov/bic/) database presently annotates the variant as of 
unknown clinical importance, pending classification, while the BRCA Share™ (UMD-
BRCA2 mutations database) (http://www.umd.be/BRCA2/) classifies it as likely benign. 
In the present study, we combined genetic approaches, including a large multi-centre case-
control study and segregation analysis in a sizable number of families, with qualitative and 
quantitative analyses of the transcripts, and Mitomycin C growth inhibition test. Our findings 
provide a robust classification of the BRCA2 c.68-7T>A variant with respect to its effect on 
cancer risk, and add evidence that splicing pattern alterations do not necessarily lead to 
pathogenicity. 
MATERIALS AND METHODS 
Nomenclature 
The nucleotide numbering was based on the reference BRCA2 cDNA sequence 
NM_000059.3. For the purposes of the study, we defined as ▼3 all BRCA2 isoforms 
retaining exon 3 and as ∆3 all BRCA2 isoforms missing exon 3, irrespective of additional 
alternative splicing events.  
Cell lines  
Epstein-Barr virus (EBV)-immortalized human lymphoblastoid cell lines (LCLs) were 
obtained as previously described (Colombo et al., 2013). In this analysis 18 LCLs were 
considered, including six LCLs obtained from women carrying the BRCA2 c.68-7T>A 
variant and 12 LCLs obtained from healthy female blood donors, recruited at the Istituto 
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Nazionale dei Tumori (INT) of Milan. The c.68-7T>A carriers had been screened in all 
coding exons and corresponding intron-exon junctions of both BRCA1 and BRCA2. 
Excluding common polymorphisms, none of them carried additional BRCA gene variants, 
with a single exception where a protein-truncating variant was detected in BRCA1 
(c.1380dupA). Only BRCA2 exon 3 was sequenced in the LCLs from normal controls and no 
pathogenic variants or VUS were observed. The two BRCA2-deficient cell lines, EUFA423 
immortalized fibroblasts (BRCA2
7691insAT/9900insA
) (Howlett et al., 2002) and pancreatic cancer 
cell line Capan1 (BRCA2
-/6174delT
) (Goggins et al., 1996) were cultured as described elsewhere 
(Feng et al., 2011). 
Cytoplasmic RNA isolation and first strand cDNA synthesis 
Cytoplasmic RNA was isolated from fresh LCLs using the Cytoplasmic & Nuclear RNA 
Purification Kit (NORGEN BIOTEK CORPORATION, Canada), including the DNase I 
treatment according to manufacturer’s instructions. The RNA purity and integrity was 
verified by measuring the A260/A280 ratio and by electrophoresis on agarose gel. For capillary 
electrophoresis (CE), allele-specific expression analysis and reverse transcriptase quantitative 
PCR (RT-qPCR), first-strand cDNA was generated using 1 g RNA, random hexamer 
primers and Maxima
TM
 H Minus RT (Thermo Scientific), following the manufacturer’s 
protocol in a final volume of 20 l. For digital PCR (dPCR), 1 g RNA was reverse 
transcribed with Prime-Script RT kit (TaKaRa Biotechnology, Japan) according to the 
manufacturer’s protocol using a mixture of random and Oligo(dT) primers. No-RT controls, 
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Capillary electrophoresis analysis  
Multiplex fluorescently-labeled PCRs were performed with primers located upstream and 
downstream of exon 3, to simultaneously amplify both ▼3 and ∆3 transcripts, followed by 
capillary electrophoresis (CE) analysis. A Beta-2-microglobulin (B2M; MIM# 109700) cDNA 
fragment of 377 bp was co-amplified to normalize CE peaks and allow comparison between 
cases and controls. The sequences of the primers are listed in Supp. Table S1. PCR 
amplifications were performed in 20 l reaction volume containing 2 l of cDNA solution 
under end-point conditions. Cycling conditions were as follows: 95°C for 7 minutes, 
followed by 35 cycles at 95°C for 30, 58°C for 30 and 72°C for 30. A final 7 minutes 
elongation step was performed at 72°C. The fluorescent amplification products were run on 
an ABI 3130 Genetic Analyzer (Applied Biosystems). GeneScan™ 500 ROX™ dye Size 
Standard was used as internal size-standard and size calling was performed with GeneMapper 
software v4.0 (Applied Biosystems). 
Assessment of allelic expression of ▼3 and ∆3 transcripts 
The allelic origin of the ▼3 and ∆3 transcripts were ascertained by amplification and 
sequencing of the region containing the common c.-26G>A variant (rs1799943) in the 5-
UTR of BRCA2. PCR reactions were performed as described above. The forward primer was 
designed to anneal to a region upstream of c.-26G>A and the reverse primers to sequences in 
exon 3 and across the exon2-exon4 junction, specific of the ▼3 and ∆3 transcripts, 
respectively (Supp. Table S1). Sequencing conditions were as previously described (Colombo 
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Quantitative PCR (qPCR) analysis 
Specific quantitative assays were designed to capture the expression levels of the ▼3 and 3 
transcripts. The primer sets (Supp. Table S1) were validated with end-point PCR reactions, 
and the specificity of the amplification products were confirmed by sequencing.  
The qPCR analysis were performed on the Eco Real-Time PCR System (Illumina) using 
SYBR

 Green I dye chemistry (KAPA SYBR

 FAST qPCR Kit, Kapa Biosystems). All 
reactions were carried out in a final volume of 10 l containing 1 l of cDNA and 200 nM of 
GUSB and ▼3 transcript specific primers, and 300 nM of 3 transcript specific primers. The 
efficiency of qPCR assays was evaluated based on a relative standard curve, using 3-fold 
serial dilutions starting from pooled control cDNAs in triplicate. The thermal profile was the 
same for all assays (95°C for 3 minutes, followed by 40 cycles of 95°C for 3 seconds and 
62°C for 20 seconds). The melting curve analysis was performed according to default 
conditions (95°C for 15seconds, 55°C for 15seconds and 95°C for 15 seconds). All  samples 
from both cases and controls were individually analyzed in triplicate, and the corresponding 
average values were considered. No template controls and no-RT controls were included in 
the analysis. The data, obtained in the form of quantification cycle (Cq), were normalized 
using the Beta-glucuronidase gene (GUSB) (de Brouwer et al., 2006). The obtained values 
were used to compute, in both normal and mutated samples, BRCA2 exon 3 exclusion rate, 
i.e. the percentage of BRCA2 mRNA isoforms missing exon 3 over the total amount of 
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The distribution of transcript levels in control and mutant LCLs was calculated by 
normalization to that of pooled control cDNAs (reference sample) using the ∆Cq method 
(Livak and Schmittgen, 2001). 
Statistical analysis was performed using GraphPad Prism Software (version 5.02). The 
significance of the results was established using the F test. 
Digital PCR (dPCR)  
The dPCR experiments were performed on a QuantStudio 3D Digital PCR 20K platform 
according to the manufacturer’s instructions (Applied Biosystem, Foster City, CA). To detect 
BRCA2 3 transcripts, we used a FAM-labeled custom designed TaqMan assay (Applied 
Biosystems) specific for the exon 2-4 junction (5-CAAAGCAG-GAAGGAATG-3). To 
detect ▼3 transcripts, we used a 2'-chloro-7'phenyl-1,4-dichloro-6-carboxy-fluorescein 
labeled (VIC-labeled) pre-designed TaqMan assay (Applied Biosystems, Hs00609076) 
specific for the exon 3-4 junction (5-AATTAGACTTAG-GAAGGAATGTTCC-3). All 
relative quantification experiments were performed combining 3 and ▼3 assays in 
individual chips. dPCR chips were analyzed in the QuantStudio 3D Analysis Suit Cloud 
Software v2.0 (Applied Biosystem, Foster City, CA), defining FAM as Target. Default 
settings were used in all cases. After reviewing automatic assessment of the chip quality by 
the software, only green flag chips (data meet all quality thresholds, review of the analysis 
result not required) and yellow flag chips (data meet all quality thresholds, but manual 
inspection is recommended) were considered for further analyses. We used the Target/Total 
ratio, FAM/(FAM+VIC), calculated by the software as a proxy for BRCA2 exon 3 exclusion 
rate. Different amounts of each sample were individually tested in 20K chips, but only data 
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from the chip with the highest precision (according to the analysis software) was included in 
the expression analysis shown in Figure 3. 
Genotyping and sample sets 
Direct genotyping of BRCA2 c.68-7T>A was conducted as part of the Collaborative 
Oncological Gene-environment Study (COGS) detailed elsewhere (Michailidou et al., 2013). 
This study included genotype results from breast cancer cases and controls participating in 
the Breast Cancer Association Consortium (BCAC; http:// bcac.ccge.medschl.cam.ac.uk/), 
and from carriers of assumed pathogenic variants in BRCA genes, participating in the 
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA; http:// 
cimba.ccge.medschl.cam.ac.uk/). The BCAC and CIMBA datasets are described in de la 
Hoya et al (de la Hoya et al., 2016). Information on breast tumor estrogen receptor and grade 
status were available for 189 variant carrier cases from BCAC. Via the Evidence-based 
Network for the Interpretation of Germline Mutant Alleles (ENIGMA; 
http://enigmaconsortium.org/) (Spurdle et al., 2012) we identified 16 families recruited 
through familial cancer clinics where at least one member tested positive for BRCA2 c.68-
7T>A, and test results (negative or positive) were available from at least one relative. All 
study participants had been previously enrolled into national or regional studies under 
ethically-approved protocols. 
Statistical methods 
The association of the BRCA2 c.68-7T>A variant with breast cancer risk was evaluated in 
BCAC using logistic regression models, as previously detailed (de la Hoya et al., 2016).  
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In addition, multifactorial likelihood analysis was conducted as detailed in the Supp. Text. In 
brief, odds for causality were calculated based on carrier frequency and ages at 
diagnosis/interview in cases and controls, as previously described (Goldgar et al., 2004).  
Bayes scores for segregation were derived as previously described (Thompson et al., 2003).  
Pathology likelihood ratios (LRs) were applied as indicated in Spurdle et al (Spurdle et al., 
2014). The segregation scores, pathology LRs and case-control LRs are mutually independent 
and were combined to derive a combined odds for causality as described previously (Goldgar 
et al., 2004; Goldgar et al., 2008). Prior probability of pathogenicity was assigned based on 
predicted effect of the variant on splicing, as derived in Vallee et al. (Vallee et al., 2016). 
Variant classification was based on the IARC 5-tier scheme (Plon et al., 2008). 
Mitomycin C (MMC) growth inhibition test and statistical analyses 
A total of 3x10
6
 cells/ml were seeded in triplicate in 25-ml flasks and grown for 72 hours in 
the absence or in the presence of MMC (Sigma-Aldrich) at a final concentration of 170 
ng/mL. Percentage of viable cells was determined using trypan blue dye exclusion assay, 
following the manufacture’s instruction (Sigma-Aldrich). Statistical differences in cell 
viability after exposure to MMC compared to controls were determined by two-tailed Student 
t-test using GraphPad Prism software. 
RESULTS 
Transcript analyses 
Confirmation of 3 transcripts increase in variant carriers 
The effect of the BRCA2 c.68-7T>A variant at the mRNA level was evaluated by 
fluorescently-labeled end-point RT-PCR on cDNAs derived from 6 LCLs obtained from 
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women carrying the investigated variant and from 12 non-variant carrier females. The visual 
inspection of the CE outputs confirmed the increase of the 3 transcripts and the 
corresponding decrease of the ▼3 transcripts in variant carriers compared to controls (a 
representative example is shown in Figure 1A), in agreement with previous studies 
(Houdayer et al., 2012; Jarhelle et al., 2016; Sanz et al., 2010; Thery et al., 2011; Vreeswijk 
et al., 2009). 
The allelic-specific expression of both the ▼3 and 3 transcripts was assessed by 
investigating the c.-26G>A variant, verified to be in linkage with the c.68-7T>A, in 
heterozygous samples (5 controls and 3 cases). Each transcript was selectively amplified in 
separate reactions and sequenced. Even considering that transcript quantification by 
sequencing analysis is not entirely accurate, it was apparent that, while in normal samples  
the levels of the 3 transcripts originating from the two alleles were comparable, in carriers 
the contribution of the variant allele was higher than that of the wild-type allele. In addition, 
it was also observed that in carriers the variant allele retained the ability to synthesize the ▼3 
transcripts. A representative example is shown in Figure 1B. 
Quantitative mRNA analyses 
To quantify the relative amount of BRCA2 ▼3 and ∆3 transcripts in LCLs from both normal 
individuals (n=12) and variant carriers (n=6), a qPCR analysis was performed. The analysis 
showed a 3.1-fold increase in the relative level of ∆3 transcripts (p<10
-4
) in carriers (average 
2.98; range 1.28-4.31) compared to controls (average 0.97; range 0.79-1.23) and a 0.5-fold 
not statistically significant (p=0.4) decrease in the relative level of ▼3 transcripts in carriers 
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The relative quantification of ∆3 and ▼3 transcripts in each sample allowed us to compare 
the exon 3 exclusion rates (see methods) in carriers and controls and to obtain a quantitative 
score reflecting the magnitude of the splicing alteration induced by the variant. The exclusion 
rate in LCLs carrying the variant allele was 5.2-fold higher than in normal LCLs (p=3.9x10
-4
) 
(Figure 3), with an average exclusion rate of 12.4% (range 6.3%-16.0%) in carriers and 2.4% 
(range 1.8%-3.4%) in controls (Supp. Figure S1).  
Subsequently, an independent dPCR-based quantitative analysis was performed to measure 
BRCA2 exon 3 exclusion rate directly in the same sample set. After excluding two outliers we 
found that the exclusion rate in LCLs carrying the variant allele (15.5%; range 14.4%-17.2%) 
was 4.2-fold higher than in normal LCLs (3.7%; range 3.0%-4.5%; p<10
-4
) (Figure 3 and 
Supp. Figure S1). 
Genetic analyses 
BRCA2 c.68-7T>A was identified in 242/41,890 (0.58%) invasive breast cancer cases and 
216/41,746 (0.52%) controls of reported European ancestry recruited through BCAC studies. 
Standard case-control analysis adjusted for six principle components yielded an odds ratio 
(OR) of 1.03 (95% CI 0.86-1.24). However, some studies indicated that they had performed 
BRCA1/2 mutation screening of cases and might have excluded cases with BRCA1/2 VUS. 
This could have created a bias due to preferential exclusion of c.68-7T>A carrier cases but 
not controls. However, the OR was similar after exclusion of four studies that performed such 
genetic testing, (OR 1.09; 95% CI 0.89 – 1.33). The odds for causality based on carrier 
frequency and ages at diagnosis/interview in these cases and controls was 9.44 x 10
-93
. There 
was also strong evidence against causality from segregation analysis (6.39 x 10
-9
) and breast 
tumor pathology (2.40 x 10
-14
). Considering all data together, and assigning prior probability 
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of 0.34 based on splicing prediction, the posterior probability of pathogenicity was calculated 
to be 7.44 x 10
-115
 (see Supp. Text for further details). 
Co-occurrence of the c.68-7T>A with pathogenic variants 
Overall 15 female individuals from 13 apparently unrelated families with clear evidence of 
the c.68-7T>A being in trans with a pathogenic variant in BRCA2 were assessed. Thirteen 
individuals from 11 families were detected through the genotyping of the CIMBA sample set, 
one was reported via the ENIGMA consortium, and another one was ascertained at INT 
(Supp. Table S2).  None of these cases was included in the RNA analyses described above. 
Evaluation of the effect of the BRCA2 c.68-7T>A on cellular sensitivity to Mitomycin C 
(MMC) 
Carriers of bi-allelic BRCA2 inactivating variants are affected with Fanconi Anemia (FA), 
complementation group D1. FA is characterized by congenital defects, including anatomical 
abnormalities, congenital disabilities and increased risk of cancer, most often acute 
myelogenous leukemia (Auerbach, 2009). In addition, the cells of FA patients exhibit 
hypersensitivity to DNA interstrand cross-links (ICLs) caused by agents such as Mitomycin 
C (Godthelp et al., 2006). A breast cancer-affected woman, with no clinical signs of FA, was 
found by segregation analysis to carry the truncating BRCA2 c.5722_5723delCT variant in 
trans with the c.68-7T>A variant (Supp. Table S2). To exclude an FA phenotype at the 
cellular level, we evaluated the sensitivity to MMC of an LCL derived from this patient. An 
LCL carrying one copy of the c.68-7T>A, without an additional BRCA2 pathogenic variant or 
VUS (BRCA2
wt/c.68-7T>A
), the MMC hypersensitive EUFA423 and Capan1 BRCA2-null cell 
lines and an LCL from a normal donor (BRCA2-proficient) were included in the assay as 
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controls. The sensitivity to MMC was evaluated by comparing the viability of MMC-treated 
cells with that of the untreated cells. As shown in Supp. Figure S2, EUFA423 (FA-D1) and 
Capan1 cells showed a significant decrease of the cellular viability (p<0.01) after exposure to 
MMC, while no differences were observed in LCLs from normal donor and carriers of 
BRCA2 c.68-7T>A, either in heterozygosity or in trans with the pathogenic variant.  
DISCUSSION 
In the present study, we analyzed the BRCA2 c.68-7T>A variant, located in the proximity of 
the acceptor site of exon 3, in order to establish its clinical relevance and association with 
breast cancer risk. In accordance with previous studies (Houdayer et al., 2012; Jarhelle et al., 
2016; Sanz et al., 2010; Thery et al., 2011; Vreeswijk et al., 2009), we observed that this 
variant leads to a modest increased expression of the transcript lacking exon 3 (∆3) in carriers 
compared to controls. Moreover, we found that in LCLs of carriers of the variant the exon 3 
exclusion rate (i.e., the relative amount of BRCA2 ∆3 transcripts) was approximately 4- to 5-
fold higher than in LCLs of controls and the total amount of ▼3 transcripts in carriers was 
approximately 50% compared to controls. The latter finding would seem to contradict the 
observation that the variant allele maintain the ability to express a transcript coding for a 
normal (full-lenght) protein. The apparent discrepancy may be explained comparing the 
overall expression of BRCA2 transcripts in cases and controls. In fact, summing up in each 
sample the amount of ▼3 and 3 transcripts assessed by qPCR, and setting as 1 the average 
expression of BRCA2 mRNA observed in our cohort, we observed notable inter-individual 
variability (ranging from 0.43 to 1.50), with many control samples clustering above the 
average (Supp. Figure S3). Hence, it is very much possible that the strong reduction in the 
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amount of ▼3 transcripts observed in carriers simply reflects random inter-individual 
variability in BRCA2 gene expression levels.  
While the above findings were confirmed using two complementary assays (qPCR and 
dPCR), it must be noted that the outcomes of transcript quantification analyses may be 
influenced by the nature of examined biological material. Therefore, the magnitude of 
changes in transcript ratio associated with the c.68-7A>T should be verified also in samples 
other than LCLs. 
The pathogenic implication of BRCA2 exon 3 deletion has been long debated. Exon 3 is 249-
bp long and its deletion does not alter the open reading frame. In addition, the ∆3 isoform has 
been described as one of the major naturally occurring alternatively splicing events in BRCA2 
(Fackenthal et al., 2016). However, the predicted protein product is expected to be lacking 
important functional activities. In fact, this exon codes for BRCA2 amino acids 23 to 106, 
including the C-terminal portion of a primary transactivating domain (PAR, amino-acid 
residues 18-60) and an auxiliary transactivating domain (AAR, residues 60-105) (Milner et 
al., 1997), whose activity may be regulated by phosphorylation (Milner et al., 2000). 
Interestingly, the region spanning residues 21-39 mediates the interaction with PALB2, a 
nuclear protein that promotes the stable intranuclear localization and accumulation of 
BRCA2, making possible its DNA recombinational repair and checkpoint functions, eliciting 
tumor suppression (Oliver et al., 2009; Xia et al., 2006). Moreover, the PALB2-binding site 
directly overlaps that of EMSY, another nuclear protein that has endogenous transcriptional 
repressor activity (Hughes-Davies et al., 2003). 
Several BRCA2 alterations causing the complete loss of exon 3 and the exclusive synthesis of 
∆3 transcripts have been ascertained, including c.316+5G>C (Bonnet et al., 2008), 
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c.316+3delA and c.68-925_316+2889del (Muller et al., 2011) and c.156_157insAlu, a variant 
reported as a founder Portuguese mutation (Peixoto et al., 2009). 
The characterization of the above variants supports the hypothesis that the exclusive 
synthesis of the ∆3 transcripts from one allele has a pathogenic effect. On the contrary, the 
association with cancer risk of variants that, like the c.68-7T>A, increase the relative amount 
of ∆3 isoforms but maintain the ability of transcribe a full-length mRNA, is presently 
unclear. Indeed, the classification of the variants with incomplete effects at the transcript 
level represents an important and challenging question. According to current ENIGMA 
criteria, splicing variants leading to in-frame deletions, but maintaining the ability to produce 
mRNA transcript(s) predicted to encode intact full-length protein, cannot be assumed as 
pathogenic or likely pathogenic, even if targeting clinical relevant domains. Such alterations 
require further investigation to assess pathogenicity.  
To address the issue, we performed a multifactorial-likelihood analysis combining the odds 
for causality derived from a large case-control study, using the datasets of BCAC, pathology 
likelihood based on breast tumor phenotype, and co-segregation data from ENIGMA. 
Overall, the posterior probability of c.68-7T>A being pathogenic was 7.44 x 10
-115
. This 
value is well below the threshold established by ENIGMA for a BRCA1/2 variant to be 
classified as class 1, i.e., not pathogenic (probability of pathogenicity < 0.001), when 
considered against characteristics of the average truncating pathogenic variant. In addition, 
the confidence interval of the odds ratio estimate (OR 1.09: 95%CI 0.89 – 1.33) excludes 
even moderate breast cancer risk (Hollestelle et al., 2010).  
Additional evidence of the non-pathogenicity of c.68-7T>A was provided by the observation 
of its occurrence in trans with a BRCA2 pathogenic variant in 15 unrelated individuals, 
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including 13 from 11 of 5,284 families recruited by CIMBA and genotyped for the variant. If 
c.68-7T>A were pathogenic, the frequency of unrelated FA affected individuals among 
CIMBA BRCA2 mutation carriers would be approximately 2.1 in 1,000, which is inconsistent 
with the frequency observed in the general population, i.e., 2 to 6 in 1,000,000 (Bogliolo and 
Surralles, 2015). Finally, no evidence of hypersensitivity to DNA interstrand cross-link (ICL) 
agents, a characteristic of FA patients, was detected in an LCL derived from one of the 
individuals carrying a pathogenic variant in trans with the c.68-7T>A. Together, these 
findings indicate that carriers of the BRCA2 c.68-7T>A variant should not be counseled to 
undergo the clinical interventions recommended to carriers of high risk BRCA gene variants.  
While the present paper was under review, a study was published claiming that the BRCA2 
c.68-7T>A variant was associated with breast cancer (Møller and Hovig, 2017). This 
conclusion was based on the detection of the variant in 17 out of 714 (2.4%; 95%CI 1.4% - 
3.8%) Norwegian unrelated breast cancer kindreds, a frequency significantly higher 
(p<0.0001) compared to the prevalence of the variant in a sample of the Norwegian 
population (3/1588 = 0.2%). Segregation data based on a single family was inconclusive (LR 
0.36), and the estimate of prospective incidence rate in 24 variant carriers overlapped that for 
the general population. The authors concluded (assumedly based on their case-control 
findings alone) that carriers of the BRCA2 c.68-7T>A variant have increased risk for breast 
cancer in families selected due to aggregation of breast cancer, and state in their discussion 
“…carriers of the variant should be informed that they probably have a clinically actionable 
pathogenic variant and referred to health care accordingly”. We believe that the conclusion 
of Moller and Hovig is unjustified, and disagree with their recommendation on clinical 
action. Our much larger study (sample size 59x for cases and 26x for controls) including 
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individuals from multiple different countries provide no evidence for increased risk of breast 
cases in familial cases carrying this variant: the OR was 1.03 (95% CI 0.86-1.24) including 
all studies, and the risk estimate was nominally greater although not significantly different 
(OR 1.09, 95% CI 0.89 – 1.33) after excluding familial breast cancer cohorts.  
The difference between the findings from our much larger case-control study and that of 
Moller and Hovig et al (Møller and Hovig, 2017) need for caution when utilizing case-control 
data for clinical interpretation of rare variants, such that significant differences in frequency 
can nonetheless be unreliable due to random error and bias arising from small sample size, 
incomplete matching of cases and controls, and, when considering familial cases, co-
occurrence of (other) risk-related genetic factors, as acknowledged by the authors themselves. 
Different hypotheses, not necessarily mutually exclusive, can be proposed to explain the lack 
of pathogenicity of c.68-7T>A despite it being spliceogenic. Firstly, the reduction in full-
length BRCA2 mRNAs in variant carriers compared to normal controls, which was not 
statistically significant, might not be enough to affect cellular tumor suppressor ability. 
Secondly, the ∆3 transcripts are predicted to lead to the synthesis of an unstable and non-
functional protein product and, therefore, unlikely to interfere with the activity of the normal 
protein - due to the loss of the PALB2 interaction domain, whose binding stabilizes the 
BRCA2 protein (Xia et al., 2006). Assuming that in the examined samples, the overall 
BRCA2 expression level from both alleles is similar, and that in carrier samples the 
accompanying normal alleles contribute on average an exclusion rate of approximately 3% as 
assessed by our quantitative analyses, we estimated, based on an average cumulative 
exclusion rate of both alleles in variant carriers of 13%, that the average exclusion rate (x) for 
the c.68-7T>A allele is close to 23% [(x%+3%)/2=13%.]. Therefore, the present study strongly 
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suggests that BRCA2 spliceogenic alleles demonstrating up to approximately 20% exon 3 
exclusion rates are not associated with high or even moderate risk of cancer. 
The classification of variants based on mRNA splicing data alone is problematic for 
spliceogenic variants that lead to equivocal or “leaky” transcript profiles. The quantitative in 
vitro transcript and genetic analyses conducted for BRCA2 c.68-7T>C provide important data 
to inform the threshold for ratio between functionally proficient and altered BRCA2 isoforms 
compatible with normal cell function. These findings might facilitate the future classification 
of rare spliceogenic variants whose relevance for cancer risk cannot easily be ascertained 
through multifactorial likelihood analyses. 
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FIGURE LEGENDS 
Figure 1. Evaluation of the effects of the BRCA2 c.68-7T>A variant at mRNA level. (A) 
Capillary electrophoresis analysis of BRCA2 cDNA showing the relative increase of 3 
transcript and decrease of ▼3 transcript in c.68-7T>A carriers compared to normal controls. 
B2M, reference transcript. Since the PCR assays were performed under end-point conditions, 
the results of these assays were not used to quantify the fold-change of 3 versus ▼3 
transcript ratio in cases compared to controls. (B) Assessment of allele-specific expression of 
the ▼3 and ∆3 transcripts in c.68-7T>A carriers and normal controls by analysis of the 
common c.-26G>A variant. The sequencing of the RT-PCR products obtained by selectively 
amplifying the ▼3 and ∆3 transcripts in separate reactions (left panels and right panels, 
respectively) shows that the variant allele, which is in linkage with the A allele of the 
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Figure 2. Relative expression of BRCA2 ▼3 and ∆3 transcripts in six c.68-7T>A carriers 
and 12 normal controls by quantitative PCR. The boxplots (displaying low, Q1, median, 
Q3, and high values) show qPCR levels of ▼3 and ∆3 transcripts in carriers and controls. 
Values are normalized to GUSB mRNA and expressed as fold difference relative to pooled 
control cDNAs using the ∆Cq method (see Materials and Methods). The analysis shows in 
carriers a statistically significant increase of the relative level of ∆3 transcripts compared to 
controls (2.98 vs. 0.97; p<0.0001). Conversely, the decrease observed in the relative level of 
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Figure 3. BRCA2 exon 3 exclusion rate in LCLs from BRCA2 c.68-7T>A carriers and 
controls. The boxplots (displaying low, Q1, median, Q3, and high values) show qPCR (left 
panel) and dPCR (right panel) measures of exclusion rate. The data is expressed as the fold-
increase relative to the average of 12 controls. Outliers (>1.5 inter quartile range, IQR) are 
displayed as small circles. On average, a 5.2-fold increase is observed in carriers according to 
qPCR data and a 4.2-fold increase according to dPCR data (3.8-fold increase if outliers are 
included in the analysis).  
 
 
